Glyburide
A sulfonylurea medication that treats type 2 diabetes and gestational diabetes by stimulating the pancreas to release more insulin and making body cells more responsive to insulin's effects. It also has cardiovascular applications under investigation, including potential benefits in atrial fibrillation management. Blood sugar monitoring is essential as hypoglycemia is the most common serious side effect.
Berat Molekul
494,0000 g/mol
LogP
4,80
TPSA
122,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Struktur 2D
Cite this structure
Embed this structure
SMILES
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
InChI
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
Molecular Formula
C23H28ClN3O5S
HBD / HBA
3 / 5
Ikatan yang Dapat Dirotasi
8
Atom Berat
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
A sulfonylurea medication that treats type 2 diabetes and gestational diabetes by stimulating the pancreas to release more insulin and making body cells more responsive to insulin's effects. It also has cardiovascular applications under investigation, including potential benefits in atrial fibrillation management. Blood sugar monitoring is essential as hypoglycemia is the most common serious side effect.
Binds to the sulfonylurea receptor (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels and triggering membrane depolarization. This opens voltage-gated calcium channels, leading to insulin exocytosis.
Yes, Glyburide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL472. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3488. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="glyburide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/glyburide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/glyburide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/glyburide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="glyburide"></drugfyi-drug>